Log in

Odonate Therapeutics Stock Forecast, Price & News

+0.10 (+0.61 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $16.51
50-Day Range
MA: $15.19
52-Week Range
Now: $16.51
Volume158,703 shs
Average Volume197,399 shs
Market Capitalization$530.42 million
P/E RatioN/A
Dividend YieldN/A
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.
Read More
Odonate Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.02 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ODT



Sales & Book Value

Annual SalesN/A
Book Value$5.06 per share


Net Income$-111,820,000.00


Market Cap$530.42 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
+0.10 (+0.61 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

How has Odonate Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ODT stock has decreased by 36.3% and is now trading at $16.51.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Odonate Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Odonate Therapeutics

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Odonate Therapeutics

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics, Inc. (NASDAQ:ODT) released its quarterly earnings results on Thursday, July, 30th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by $0.11.
View Odonate Therapeutics' earnings history

What price target have analysts set for ODT?

2 Wall Street analysts have issued 1 year price objectives for Odonate Therapeutics' shares. Their forecasts range from $26.00 to $50.00. On average, they anticipate Odonate Therapeutics' stock price to reach $38.00 in the next year. This suggests a possible upside of 130.2% from the stock's current price.
View analysts' price targets for Odonate Therapeutics

Are investors shorting Odonate Therapeutics?

Odonate Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 2,060,000 shares, an increase of 32.9% from the August 31st total of 1,550,000 shares. Based on an average trading volume of 377,300 shares, the short-interest ratio is presently 5.5 days. Approximately 6.9% of the shares of the company are sold short.
View Odonate Therapeutics' Short Interest

Who are some of Odonate Therapeutics' key competitors?

What other stocks do shareholders of Odonate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), The Boeing (BA), Bausch Health Companies (BHC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Athenex (ATNX), BioCryst Pharmaceuticals (BCRX) and Crispr Therapeutics (CRSP).

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the following people:
  • Mr. Kevin C. Tang, Chairman & CEO (Age 53, Pay $1)
  • Mr. John G. Lemkey, Chief Operating Officer (Age 39, Pay $439.64k)
  • Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 66, Pay $545.94k)
  • Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
  • Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 44)

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Who are Odonate Therapeutics' major shareholders?

Odonate Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.53%). Company insiders that own Odonate Therapeutics stock include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang.
View institutional ownership trends for Odonate Therapeutics

Which institutional investors are buying Odonate Therapeutics stock?

ODT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought Odonate Therapeutics stock in the last two years include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang.
View insider buying and selling activity for Odonate Therapeutics

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $16.51.

How big of a company is Odonate Therapeutics?

Odonate Therapeutics has a market capitalization of $530.42 million. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 134 workers across the globe.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is www.odonate.com.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.